CDMO Pfizer CentreOne opens new manufacturing facility in Japan

| By | CDMO, Contract Manufacturing, Pfizer, Pharmaceutical Manufacturing

Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, announced that it is now offering services in Nagoya, Japan.

The Nagoya site will provide in-country manufacture of highly potent oral solid dosage forms. It will also provide gateway services into Japan – inspection, packaging and testing – for highly potent oral solid drugs and sterile injectables made by Pfizer CentreOne outside the country.

“We’re pleased to add Pfizer’s Nagoya facility to our manufacturing footprint,” said Peter Stevenson, vice president of contract manufacturing, Pfizer CentreOne. “Pfizer has been manufacturing pharmaceuticals in Japan for 50 years. We deeply understand the exacting expectations of Japanese pharmacies and patients, along with the challenges they entail. That knowledge can help our biopharmaceutical partners attain a marketing edge, whether they manufacture their drug at our Nagoya site or bring it into Japan through our Japan gateway services.”

The Nagoya facility provides state-of-the-art cGMP manufacturing of highly potent oral solid drugs that require containment (to protect personnel from contact with hazardous materials) and segregation (to prevent cross-contamination of drugs in the plant).

The new site manufactures: highly active compounds, immunosuppresive drugs, sensitizing agents and controlled drugs. Dosage forms include high and multiple doses; combination products; multiple release and fixed dose.

SOURCE: pfizer centreone
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.